Champions Biotechnology receives U.S. patent for its tubulin inhibitors

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a drug development company with a preclinical platform able to predict clinical effectiveness, accelerate development and enhance the value of oncology drugs, today announced that the United States Patent and Trademark Office issued a patent on September 29, 2009 for the company's tubulin inhibitors, including its lead compound SG410. U.S. Patent No. 7,595,326 entitled "Synthesis of Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs" protects the Company's composition of matter, pharmaceutical composition, and method of treatment for SG410. The patent is owned by Champions Biotechnology.

"This patent solidifies Champions' intellectual property position on SG410. We believe that SG410, in the new Neowater formulation we developed, has the potential to significantly impact the treatment of cancer," said Doug Burkett, Ph.D., President of Champions Biotechnology, Inc. "SG410 is Champions' first internal compound and is currently undergoing Biomerk Tumorgraft(TM) evaluation. The results of SG410 tests in our predictive platform are expected to be available soon. We are also actively evaluating high potential compounds to build our oncology drug pipeline and expect to in-license additional drugs in the near future. Studies suggest that evaluations of compounds through Biomerk Tumorgrafts will lead to more successful and efficient clinical development."